Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | WHR1 | P49842 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | IDH2 | P48735 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22505630 | 0.84 | PKM (0.38) | EPHX2DGAT1 | |
| SCHEMBL1717640 | 0.82 | EPHX2 (0.36) | EPHX2KDM1AIDH1IDH2 | |
| Trifluoroacetic Acid SCHEMBL29221249 | 0.81 | EPHX2 (0.41) | EPHX2KDM1AWHR1IDH1IDH2 | |
| Trifluoroacetic Acid SCHEMBL16050159 | 0.80 | PDK1 (0.39) | EPHX2 | |
| Trifluoroacetic Acid SCHEMBL4114059 | 0.80 | PDK1 (0.39) | EPHX2 | |
| Hypochlorous Acid SCHEMBL28596409 | 0.80 | EPHX2 (0.37) | EPHX2KDM1AIDH1IDH2MAOB | |
| Hydrochloric Acid SCHEMBL15550997 | 0.80 | EPHX2 (0.35) | EPHX2KDM1AIDH1IDH2 | |
| Hydrochloric Acid SCHEMBL29093704 | 0.80 | EPHX2 (0.35) | EPHX2KDM1AIDH1IDH2 | |
| Trifluoroacetic Acid SCHEMBL3862637 | 0.79 | PDK1 (0.42) | EPHX2 | |
| Hydrochloric Acid SCHEMBL22042887 | 0.78 | EPHX2 (0.34) | EPHX2IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | AbbVie S.à.r.l. (LU) | 2019-04-16 | — | — | US | disclosed |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | GALAPAGOS SASU (FR) | 2018-04-19 | — | — | US | disclosed |
| US-9890158-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2018-02-13 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | EPHX2 3605/4885KDM1A 4484/4885DGAT1 4639/4885 |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | EPHX2 2986/4885KDM1A 4588/4885DGAT1 4590/4885 |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | CFTR, CHRM3, P2RY1 | EPHX2 4009/4885KDM1A 4351/4885DGAT1 4601/4885 |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, CHRM3, P2RY1 | EPHX2 4009/4885KDM1A 4351/4885DGAT1 4601/4885 |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, P2RY1, P2RX5 | EPHX2 3605/4885KDM1A 4484/4885DGAT1 4639/4885 |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | EPHX2 3605/4885KDM1A 4484/4885DGAT1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.